PLRX – pliant therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Pliant Therapeutics First Quarter 2024 Earnings: US$0.78 loss per share (vs US$0.67 loss in 1Q 2023) [Yahoo! Finance]
Pliant Therapeutics, Inc. (NASDAQ: PLRX) had its price target lowered by analysts at Citigroup Inc. from $45.00 to $44.00. They now have a "buy" rating on the stock.
Pliant Therapeutics, Inc. (NASDAQ: PLRX) had its price target lowered by analysts at Royal Bank of Canada from $54.00 to $45.00. They now have an "outperform" rating on the stock.
Pliant Therapeutics, Inc. (NASDAQ: PLRX) had its price target raised by analysts at Oppenheimer Holdings Inc. from $47.00 to $48.00. They now have an "outperform" rating on the stock.
Pliant Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver International Liver Congress™ [Yahoo! Finance]
Form 10-Q PLIANT THERAPEUTICS, For: Mar 31
Form 8-K PLIANT THERAPEUTICS, For: May 06
Form 4 PLIANT THERAPEUTICS, For: May 02 Filed by: Cummings Keith Lamont
Form DEFA14A PLIANT THERAPEUTICS,
Form DEF 14A PLIANT THERAPEUTICS, For: Dec 31
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.